Description:GDC-0994, with the CAS number 1453848-26-4, is a small molecule inhibitor primarily targeting the mitogen-activated protein kinase (MAPK) pathway, specifically the extracellular signal-regulated kinase (ERK). It is designed to interfere with the signaling pathways that are often dysregulated in various cancers, making it a candidate for cancer therapy. The compound exhibits selective inhibition of ERK, which is crucial for cell proliferation and survival. GDC-0994 has been evaluated in preclinical studies and clinical trials for its efficacy in treating tumors with specific genetic mutations. Its pharmacological profile includes properties such as oral bioavailability and a favorable safety margin, although detailed toxicity and side effect profiles are typically assessed during clinical development. The compound's structure features a unique arrangement of functional groups that contribute to its binding affinity and specificity for the target enzyme. Overall, GDC-0994 represents a promising approach in targeted cancer therapy, particularly in the context of personalized medicine.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![1-[(1S)-1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-[(1-methyl-1H-pyrazol-5-yl)amino]-4-pyrim…](https://static.cymitquimica.com/products/3D/thumb/FC103437.jpg)
